Grant Agreement	12 Months Ended
Dec. 31, 2021
Grant Agreement [Abstract]
Grant Agreement	4. Grant Agreement Bill & Melinda Gates Foundation Grant Agreement In support of the Company’s development of a COVID-19 vaccine for pandemic use, in September 2020, the Company entered into the grant agreement (the “Grant Agreement”) with the Bill & Melinda Gates Foundation (“BMGF”), under which it was awarded a grant totaling up to $10.0 million (the “Grant”). The Grant supported development activities, including the Company’s regulatory filing preparations and planned Phase 1 clinical trial. Unless terminated earlier by BMGF, the Grant Agreement will continue in effect until March 31, 2022. The Company concurrently entered into a Global Access Commitments Agreement (“GACA”) with BMGF as part of the Grant Agreement. Under the terms of the GACA, among other things, the Company agreed to make a certain amount of its COVID-19 vaccine available and accessible at affordable pricing to people in certain low- and middle-income countries, if the vaccine is commercialized. Payments received in advance that are related to future performance are deferred and recognized as revenue when the research and development activities are performed. Cash payments received under the Grant Agreement are restricted as to their use until eligible expenditures are incurred. At December 31, 2021, the Company had $0.6 million of restricted cash and deferred revenue, and at December 31, 2020, had $2.3 million of restricted cash and deferred revenue, representing funds received from BMGF and the Company's estimate of costs to be reimbursed and revenue to be recognized, respectively, in the next twelve months under the Grant Agreement. During the years ended December 31, 2021 and 2020, the Company received $6.0 million and $4.0 million in funding, respectively, from BMGF. During the years ended December 31, 2021 and 2020, the Company recognized revenue from the Grant Agreement of $7.8 million and $1.6 million, respectively, and has recognized approximately $9.4 million in revenue since the inception of the Grant Agreement. As of December 31, 2021, the Company has received the full $10.0 million in funding under the Grant Agreement.

Grant Agreement

12 Months Ended

Dec. 31, 2021

4. Grant Agreement

Bill & Melinda Gates Foundation Grant Agreement

In support of the Company’s development of a COVID-19 vaccine for pandemic use, in September 2020, the Company entered into the grant agreement (the “Grant Agreement”) with the Bill & Melinda Gates Foundation (“BMGF”), under which it was awarded a grant totaling up to $10.0 million (the “Grant”). The Grant supported development activities, including the Company’s regulatory filing preparations and planned Phase 1 clinical trial. Unless terminated earlier by BMGF, the Grant Agreement will continue in effect until March 31, 2022. The Company concurrently entered into a Global Access Commitments Agreement (“GACA”) with BMGF as part of the Grant Agreement. Under the terms of the GACA, among other things, the Company agreed to make a certain amount of its COVID-19 vaccine available and accessible at affordable pricing to people in certain low- and middle-income countries, if the vaccine is commercialized.

Payments received in advance that are related to future performance are deferred and recognized as revenue when the research and development activities are performed. Cash payments received under the Grant Agreement are restricted as to their use until eligible expenditures are incurred.

At December 31, 2021, the Company had $0.6 million of restricted cash and deferred revenue, and at December 31, 2020, had $2.3 million of restricted cash and deferred revenue, representing funds received from BMGF and the Company's estimate of costs to be reimbursed and revenue to be recognized, respectively, in the next twelve months under the Grant Agreement.

During the years ended December 31, 2021 and 2020, the Company received $6.0 million and $4.0 million in funding, respectively, from BMGF.

During the years ended December 31, 2021 and 2020, the Company recognized revenue from the Grant Agreement of $7.8 million and $1.6 million, respectively, and has recognized approximately $9.4 million in revenue since the inception of the Grant Agreement. As of December 31, 2021, the Company has received the full $10.0 million in funding under the Grant Agreement.